Relocation Allowances: Taxes on Travel, Transportation, and Relocation Expenses, 67462 [2019-26511]
Download as PDF
67462
Federal Register / Vol. 84, No. 237 / Tuesday, December 10, 2019 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2019–26593 Filed 12–9–19; 8:45 am]
BILLING CODE 8070–01–C
Agency for Healthcare Research and
Quality
GENERAL SERVICES
ADMINISTRATION
[Notice–MA–2019–10; Docket No. 2019–
0002; Sequence No. 32]
Relocation Allowances: Taxes on
Travel, Transportation, and Relocation
Expenses
Office of Government-wide
Policy (OGP), General Services
Administration (GSA).
AGENCY:
ACTION:
The purpose of this notice is
to inform Federal agencies that FTR
Bulletin 20–02, pertaining to travel,
transportation, and relocation
allowances impacted by recent changes
to Federal tax law, has been published
and is now available online at
www.gsa.gov/ftrbulletin. This bulletin
contains certain examples and tables
that were removed from the FTR as a
result of FTR Amendment 2020–02,
published by GSA on November 25,
2019, and issued as a direct final rule.
This bulletin also rescinds FTR
Bulletins 18–05 and 19–02 now that
FTR Amendment 2020–02 has been
issued, amending the FTR in line with
changes to the Internal Revenue Code.
SUMMARY:
Applicable: This notice applies
to employees who are authorized
reimbursement for relocation expenses
under the FTR and who receive some or
all reimbursements, direct payments, or
indirect payments on or after January 1,
2018, and on or before December 31,
2025.
DATES:
For
clarification of content, please contact
Mr. Rick Miller, Program Analyst, Office
of Government-wide Policy, Office of
Asset and Transportation Management,
at 202–501–3822, or by email at
travelpolicy@gsa.gov. Please cite Notice
of FTR Bulletin 20–02.
jbell on DSKJLSW7X2PROD with NOTICES
Jessica Salmoiraghi,
Associate Administrator, Office of
Government-wide Policy.
[FR Doc. 2019–26511 Filed 12–9–19; 8:45 am]
BILLING CODE 6820–14–P
VerDate Sep<11>2014
17:08 Dec 09, 2019
Jkt 250001
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submissions.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Maternal and Fetal Effects of Mental
Health Treatments in Pregnant and
Breastfeeding Women: A Systematic
Review of Pharmacological
Interventions, which is currently being
conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program.
Access to published and unpublished
pertinent scientific information will
improve the quality of this review.
DATES: Submission Deadline on or
before 30 days after date of publication.
ADDRESSES:
Email Submissions: epc@
ahrq.hhs.gov.
Print Submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
SUMMARY:
Notice.
FOR FURTHER INFORMATION CONTACT:
Supplemental Evidence and Data
Request on Maternal and Fetal Effects
of Mental Health Treatments in
Pregnant and Breastfeeding Women: A
Systematic Review of Pharmacological
Interventions
FOR FURTHER INFORMATION CONTACT:
Jenae Benns, Telephone: 301–427–1496
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Maternal and Fetal Effects
of Mental Health Treatments in
Pregnant and Breastfeeding Women: A
Systematic Review of Pharmacological
Interventions. AHRQ is conducting this
systematic review pursuant to Section
902(a) of the Public Health Service Act,
42 U.S.C. 299a(a).
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Maternal and Fetal Effects
of Mental Health Treatments in
Pregnant and Breastfeeding Women: A
Systematic Review of Pharmacological
Interventions, including those that
describe adverse events. The entire
research protocol, including the key
questions, is also available online at:
https://effectivehealthcare.ahrq.gov/
topics/mental-health-pregnancy/
protocol.
This is to notify the public that the
EPC Program would find the following
information on Maternal and Fetal
Effects of Mental Health Treatments in
Pregnant and Breastfeeding Women: A
Systematic Review of Pharmacological
Interventions helpful:
D A list of completed studies that
your organization has sponsored for this
indication. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements: Study number, study period,
design, methodology, indication and
diagnosis, proper use instructions,
inclusion and exclusion criteria,
primary and secondary outcomes,
baseline characteristics, number of
patients screened/eligible/enrolled/lost
to follow-up/withdrawn/analyzed,
effectiveness/efficacy, and safety results.
D A list of ongoing studies that your
organization has sponsored for this
indication. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including a study number, the
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, and primary and secondary
outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this indication and an
index outlining the relevant information
in each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on indications not included
E:\FR\FM\10DEN1.SGM
10DEN1
Agencies
[Federal Register Volume 84, Number 237 (Tuesday, December 10, 2019)]
[Notices]
[Page 67462]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26511]
=======================================================================
-----------------------------------------------------------------------
GENERAL SERVICES ADMINISTRATION
[Notice-MA-2019-10; Docket No. 2019-0002; Sequence No. 32]
Relocation Allowances: Taxes on Travel, Transportation, and
Relocation Expenses
AGENCY: Office of Government-wide Policy (OGP), General Services
Administration (GSA).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The purpose of this notice is to inform Federal agencies that
FTR Bulletin 20-02, pertaining to travel, transportation, and
relocation allowances impacted by recent changes to Federal tax law,
has been published and is now available online at www.gsa.gov/ftrbulletin. This bulletin contains certain examples and tables that
were removed from the FTR as a result of FTR Amendment 2020-02,
published by GSA on November 25, 2019, and issued as a direct final
rule. This bulletin also rescinds FTR Bulletins 18-05 and 19-02 now
that FTR Amendment 2020-02 has been issued, amending the FTR in line
with changes to the Internal Revenue Code.
DATES: Applicable: This notice applies to employees who are authorized
reimbursement for relocation expenses under the FTR and who receive
some or all reimbursements, direct payments, or indirect payments on or
after January 1, 2018, and on or before December 31, 2025.
FOR FURTHER INFORMATION CONTACT: For clarification of content, please
contact Mr. Rick Miller, Program Analyst, Office of Government-wide
Policy, Office of Asset and Transportation Management, at 202-501-3822,
or by email at [email protected]. Please cite Notice of FTR Bulletin
20-02.
Jessica Salmoiraghi,
Associate Administrator, Office of Government-wide Policy.
[FR Doc. 2019-26511 Filed 12-9-19; 8:45 am]
BILLING CODE 6820-14-P